Our HIV diagnostic solutions enable lifesaving decisions to be made that have a powerful impact on people, governments, and society. By bringing care where it’s needed most, vulnerable communities have unprecedented access to treatment – and healthcare professionals have what they need to diagnose, treat, and stop HIV transmission.
UNAIDS calls for nothing less than the end of the AIDS epidemic by 2030.1 These ambitious goals call for rapidly scaling up diagnosis, treatment, and viral suppression, especially in vulnerable populations. With industry-leading products along the cascade of care, Abbott is uniquely able to partner with you to make sure every goal is achieved.
The results speak for themselves. Since 2010, improved access to testing and treatment has resulted in a 26% decline in AIDS-related deaths globally.2
Abbott is #1 globally among manufacturers of HIV rapid tests.3
Get the leading edge in HIV prevention and diagnosis with these Abbott products.
We’re the global leader in rapid point of care testing for HIV.3 Right now, in more than 120 countries, healthcare professionals are using Abbott HIV tests to identify infections earlier, prevent onward transmissions, and change the trajectory of the AIDS epidemic for the better.
Every child deserves a HIV-free beginning.
Elimination of new HIV infections among infants is an important part of ending the HIV epidemic. It starts with reducing mother-to-child transmission of both HIV and syphilis. Access to syphilis/HIV diagnostics and timely treatment can minimize the infection risks faced by the unborn child. For infants that acquire HIV, early infant diagnosis with accurate molecular testing can be the difference between life and death. Find the best solution for your littlest patients.
On the fast track to ending the HIV epidemic: Active Case Finding.
A crucial step to reaching the UNAIDS goals is to make sure people with HIV can be accurately identified now. Identifying HIV-positive patients now not only facilitates fast and appropriate linkage to care – it helps to prevent further transmission of the disease. Our accessible, scalable POC tests for active case finding are designed to go wherever they’re needed – including remote decentralized settings.
On the path to better health, faster: effective management.
The faster you get the results, the sooner you can make life saving decisions. Our rapid CD4 test helps caregivers establish a baseline immune function and assess clinical outcome – while the patient is still there – to expedite treatment and management decisions. The m-PIMA™ Analyser brings HIV viral load testing to a wide range of decentralized settings.
Our industry-leading solutions help you screen for HIV-associated TB in minutes.
Studies show that HIV-positive people tend to be at higher risk of suffering from a range of non-AIDS co-morbidities.4 Tuberculosis (TB) is notoriously difficult to diagnose in HIV-infected people, with tools such sputum smear microscopy and chest radiography offering low sensitivity and specificity in this patient group. Helping you diagnose active TB in HIV-positive patients with result in minutes, the TB LAM Ag test offers the greatest sensitivity in the sickest patients.5
Decentralized healthcare management
What if you could give your patients confidence that they will be tested efficiently and accurately? Data Point is a complete solution for managing point-of-care device health, monitoring stock and reviewing operator efficiency.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage. Not all products are available in all regions. Check with your local representative for availability in specific markets. For In Vitro Diagnostic Use Only. For the use of registered medical practitioners, hospitals and Laboratories only.
Based on your current location, the content on this page may not be relevant for your country.
